Tumor necrosis factor α induces p53 up-regulated modulator of apoptosis expression in colorectal cancer cell lines

Diseases of the Colon and Rectum

Volumn 53, Issue 3, 2010, Pages 257-263

  Pastor, Danielle M ^a   Irby, Rosalyn B ^a   Poritz, Lisa S ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

Colorectal cancer; Inflammatory bowel disease; p53; PUMA; Tumor necrosis factor

Indexed keywords

MESSENGER RNA; NUCLEAR PROTEIN; PROTEIN P53; TUMOR NECROSIS FACTOR ALPHA; APOPTOSIS REGULATORY PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL; CARCINOGENESIS; CELLULAR DISTRIBUTION; COLORECTAL CANCER; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE TEST; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA TRANSCRIPTION; WILD TYPE; ANALYSIS OF VARIANCE; COLORECTAL TUMOR; DRUG EFFECT; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; UPREGULATION;

ANALYSIS OF VARIANCE; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOBLOTTING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 77949908594     PISSN: 00123706     EISSN: 15300358     Source Type: Journal    
DOI: 10.1007/DCR.0b013e3181c522c7     Document Type: Article

References (27)

1. Rudy DR, Zdon MJ. Update on colorectal cancer. Am Fam Physician. 2000;61:1759-1770, 73-74.
2. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526-535. (Pubitemid 32234798)
3. Wang X, Lin Y. Tumor necrosis factor and cancer, buddies or foes? Acta Pharmacologica Sinica. 2008;29:1275-1288.
4. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759-767. (Pubitemid 20185636)
5. Itzkowitz SH, Yio X. Inflammation and cancer IV: colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol. 2004;287: G7-G17. (Pubitemid 38802113)
6. Colliver DW, Crawford NP, Eichenberger MR, et al. Molecular profiling of ulcerative colitis-associated neoplastic progression. Exp Mol Pathol. 2006;80:1-10.
7. Kern SE, Redston M, Seymour AB, et al. Molecular genetic profiles of colitis-associated neoplasms. Gastroenterology. 1994;107:420-428. (Pubitemid 24233316)
8. Tomlinson I, Ilyas M, Johnson V, et al. A comparison of the genetic pathways involved in the pathogenesis of three types of colorectal cancer. J Pathol. 1998;184:148-152. (Pubitemid 28088422)
9. Dignass AU, Baumgart DC, Sturm A. Review article: the aetiopathogenesis ofinflammatory bowel disease-immunology and repair mechanisms. Aliment Pharmacol Ther. 2004;20(suppl 4): 9):9-17. (Pubitemid 39319241)
10. Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell. 2001;7:683-694. (Pubitemid 32706359)
11. Yu J, Zhang L, Hwang PM, Kinzler KW, Vogelstein B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell. 2001;7:673-682. (Pubitemid 32706358)
12. Harpaz N, Talbot IC. Colorectal cancer in idiopathic inflammatory bowel disease. Semin Diagn Pathol. 1996;13:339-357. (Pubitemid 26399400)
13. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer: a population-based study. N Engl J Med. 1990;323:1228-1233. (Pubitemid 20366527)
14. Niessner M, Volk BA. Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR). Clin Exp Immunol. 1995;101:428-435.
15. Murch SH, Braegger CP, Walker-Smith JA, MacDonald TT. Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut. 1993;34:1705-1709.
16. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275-2285. (Pubitemid 43736578)
17. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med. 2005;352:351-361.
18. Chakravarty EF, Michaud K, Wolfe F. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol. 2005;32:2130-2135. (Pubitemid 41587856)
19. Keystone EC. Advances in targeted therapy: safety of biological agents. Ann Rheum Dis. 2003;62(suppl 2): ii34-ii36.
20. Popivanova BK, Kitamura K, Wu Y, et al. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest. 2008;118:560-570. (Pubitemid 351206546)
21. Harrison ML, Obermueller E, Maisey NR, et al. Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. J Clin Oncol. 2007;25:4542-4549. (Pubitemid 350035310)
22. Sato A, MacHinami R. p53 immunohistochemistry of ulcerative colitis-associated with dysplasia and carcinoma. Pathol Int. 1999;49:858-868.
23. Arai N, Mitomi H, Ohtani Y, Igarashi M, Kakita A, Okayasu I. Enhanced epithelial cell turnover associated with p53 accumulation and high p21WAF1/CIP1 expression in ulcerative colitis. Mod Pathol. 1999;12:604-611. (Pubitemid 29279714)
24. Mitsuhashi J, Mikami T, Saigenji K, Okayasu I. Significant correlation of morphological remodeling in ulcerative colitis with disease duration and between elevated p53 and p21 expression in rectal mucosa and neoplastic development. Pathol Int. 2005;55:113-121. (Pubitemid 40477222)
25. Alkim C, Savas B, Ensari A, et al. Expression of p53, VEGF, microvessel density, and cyclin-D1 in noncancerous tissue of inflammatory bowel disease. Dig Dis Sci. 2009;54:1979-1984.
26. Ahnen DJ. Tissue markers of colon cancer risk. Gastrointest Endosc. 1999;49: S50 -S59. (Pubitemid 29129867)
27. Brentnall TA, Crispin DA, Rabinovitch PS, et al. Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology. 1994;107:369-378.